When the FDA unexpectedly uploaded around 200 drug rejection letters this week, the regulator provided an in-depth view | ...

While Astellas’ Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved for menopause, Lynkuet is the first ...

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Renee Gala joins a short list of female biopharma chief executives as she is set to take the reins at Jazz Pharmaceuticals, ...

Eight drugmakers agreed to put legal claims stemming from their roles in the U.S. | Viatris, Hikma, Amneal, Apotex, Indivior, ...

AstraZeneca spinout Dizal Pharmaceuticals won an FDA accelerated approval for sunvozertinib for previously treated EGFR ex 20 ...

According to a pair of recent rulings by the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA), Jazz ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Nearly 70 years into her history, Barbie is still undergoing regular makeovers. | Nearly 70 years into her history, Barbie is ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

After reporting a 15% sequential decline in Izervay sales for the opening quarter of this year, Astellas has reversed the ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...